{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T03:52:14Z","timestamp":1789012334599,"version":"build-2803163510"},"reference-count":39,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100010451","name":"Health and Family Planning Commission of Hunan Province","doi-asserted-by":"publisher","award":["20200022"],"award-info":[{"award-number":["20200022"]}],"id":[{"id":"10.13039\/501100010451","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["71874209"],"award-info":[{"award-number":["71874209"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of\u00a0Hunan Province","doi-asserted-by":"publisher","award":["2019JJ40411"],"award-info":[{"award-number":["2019JJ40411"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.clinthera.2021.05.015","type":"journal-article","created":{"date-parts":[[2021,6,27]],"date-time":"2021-06-27T16:12:41Z","timestamp":1624810361000},"page":"1253-1264.e5","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["First-line Daratumumab in Addition to Chemotherapy for Newly Diagnosed Multiple Myeloma Patients Who are Transplant Ineligible: A Cost-Effectiveness Analysis"],"prefix":"10.1016","volume":"43","author":[{"given":"SiNi","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JianHe","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"LiuBao","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ChongQing","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"XiaoHui","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"CiYan","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YaMin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"XiaoMin","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2021.05.015_bib0001","article-title":"Multiple myeloma: an overview of management","volume":"13","author":"Bird","year":"2019","journal-title":"Palliat Care Soc Pract"},{"key":"10.1016\/j.clinthera.2021.05.015_bib0002","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/ajh.25791","article-title":"Multiple myeloma: 2020 update on diagnosis, risk-stratification and management","volume":"95","author":"Rajkumar","year":"2020","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clinthera.2021.05.015_bib0003","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.clinthera.2019.12.007","article-title":"Economic evaluation of adding daratumumab to a regimen of bortezomib\u00a0+\u00a0dexamethasone in relapsed or refractory multiple myeloma: based on the latest updated analysis of CASTOR","volume":"42","author":"Zeng","year":"2020","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2021.05.015_bib0004","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.6004\/jnccn.2019.0049","article-title":"NCCN Guidelines Insights: Multiple Myeloma, Version 1.2020","volume":"17","author":"Kumar","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.clinthera.2021.05.015_bib0005","first-page":"7","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clinthera.2021.05.015_bib0006","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13045-016-0283-0","article-title":"Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma","volume":"9","author":"Sanchez","year":"2016","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.clinthera.2021.05.015_bib0007","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","article-title":"Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma","volume":"128","author":"Krejcik","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2021.05.015_bib0008","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.4049\/jimmunol.1003032","article-title":"Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors","volume":"186","author":"de Weers","year":"2011","journal-title":"J Immunol"},{"key":"10.1016\/j.clinthera.2021.05.015_bib0009","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","article-title":"Daratumumab plus lenalidomide and dexamethasone for untreated myeloma","volume":"380","author":"Facon","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2021.05.015_bib0010","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.3324\/haematol.2018.194118","article-title":"Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR","volume":"103","author":"Spencer","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.clinthera.2021.05.015_bib0011","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.3324\/haematol.2018.194282","article-title":"Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX","volume":"103","author":"Dimopoulos","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.clinthera.2021.05.015_bib0012","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S0140-6736(19)32956-3","article-title":"Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial","volume":"395","author":"Mateos","year":"2020","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.clinthera.2021.05.015_bib0013","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa1714678","article-title":"Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma","volume":"378","author":"Mateos","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2021.05.015_bib0014","series-title":"FDA approves daratumumab for transplant-eligible multiple myeloma","year":"2019"},{"key":"10.1016\/j.clinthera.2021.05.015_bib0015","series-title":"Darzalex: summary of product characteristics","year":"2018"},{"key":"10.1016\/j.clinthera.2021.05.015_bib0016","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1056\/NEJMp1405158","article-title":"Updating cost-effectiveness\u2014the curious resilience of the $50,000-per-QALY threshold","volume":"371","author":"Neumann","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2021.05.015_bib0017","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/1471-2288-11-139","article-title":"Improved curve fits to summary survival data: application to economic evaluation of health technologies","volume":"11","author":"Hoyle","year":"2011","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.clinthera.2021.05.015_bib0018","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0121353","article-title":"A review and comparison of methods for recreating individual patient data from published Kaplan-Meier survival curves for economic evaluations: a simulation study","volume":"10","author":"Wan","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.clinthera.2021.05.015_bib0019","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1016\/j.clinthera.2018.05.012","article-title":"Cost-effectiveness of daratumumab-based triplet therapies in patients with relapsed or refractory multiple myeloma","volume":"40","author":"Zhang","year":"2018","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2021.05.015_bib0020","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1002\/cncr.30666","article-title":"Economic evaluation of nivolumab as a second-line treatment for advanced renal cell carcinoma from US and Chinese perspectives","volume":"123","author":"Wan","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.clinthera.2021.05.015_bib0021","first-page":"68","article-title":"Division of Vital Statistics. United States Life Tables, 2017","author":"Arias","year":"2019","journal-title":"Natl Vital Stat Rep"},{"key":"10.1016\/j.clinthera.2021.05.015_bib0022","doi-asserted-by":"crossref","first-page":"243","DOI":"10.3111\/13696998.2015.1115407","article-title":"Cost-effectiveness of lenalidomide plus dexamethasone vs. bortezomib plus melphalan and prednisone in transplant-ineligible US patients with newly-diagnosed multiple myeloma","volume":"19","author":"Usmani","year":"2016","journal-title":"J Med Econ"},{"key":"10.1016\/j.clinthera.2021.05.015_bib0023","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1080\/13696998.2016.1194278","article-title":"Cost-effectiveness of adding carfilzomib to lenalidomide and dexamethasone in relapsed multiple myeloma from a US perspective","volume":"19","author":"Jakubowiak","year":"2016","journal-title":"J Med Econ"},{"key":"10.1016\/j.clinthera.2021.05.015_bib0024","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s10198-012-0395-6","article-title":"Lenalidomide for multiple myeloma: cost-effectiveness in patients with one prior therapy in England and Wales","volume":"14","author":"Brown","year":"2013","journal-title":"Eur J Health Econ"},{"key":"10.1016\/j.clinthera.2021.05.015_bib0025","series-title":"ASP drug pricing files","year":"2020"},{"issue":"3","key":"10.1016\/j.clinthera.2021.05.015_bib0026","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.clinthera.2019.01.009","article-title":"Cost offsets in the treatment journeys of patients with relapsed\/refractory multiple myeloma","volume":"41","author":"Ailawadhi","year":"2019","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2021.05.015_bib0027","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1016\/j.clinthera.2017.08.010","article-title":"Cost-effectiveness of pomalidomide, carfilzomib, and daratumumab for the treatment of patients with heavily pretreated relapsed-refractory multiple myeloma in the United States","volume":"39","author":"Pelligra","year":"2017","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2021.05.015_bib0028","unstructured":"US Department of Labor. Calculators. http:\/\/www.bls.gov\/data\/#calculators. Accessed 13 April 2020."},{"key":"10.1016\/j.clinthera.2021.05.015_bib0029","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.6004\/jnccn.2020.7587","article-title":"Cost-Effectiveness of maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer","volume":"18","author":"Wu","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.clinthera.2021.05.015_bib0030","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.eururo.2017.07.041","article-title":"Cost effectiveness of nivolumab in advanced renal cell carcinoma","volume":"73","author":"Sarfaty","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.clinthera.2021.05.015_bib0031","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1136\/jech.2007.059576","article-title":"Decision modelling for health economic evaluation","volume":"61","author":"Aalabaf-Sabaghi","year":"2007","journal-title":"J Epidemiol Commun Health"},{"key":"10.1016\/j.clinthera.2021.05.015_bib0032","series-title":"SEER Cancer Statistics Review, 1975-2017","year":"2020"},{"key":"10.1016\/j.clinthera.2021.05.015_bib0033","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1001\/jamaoncol.2018.7086","article-title":"First-line nivolumab plus ipilimumab vs sunitinib for metastatic renal cell carcinoma: a cost-effectiveness analysis","volume":"5","author":"Wan","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clinthera.2021.05.015_bib0034","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1111\/j.1524-4733.2008.00358.x","article-title":"Optimal cost-effectiveness decisions: the role of the cost-effectiveness acceptability curve (CEAC), the cost-effectiveness acceptability frontier (CEAF), and the expected value of perfection information (EVPI)","volume":"11","author":"Barton","year":"2008","journal-title":"Value Health"},{"key":"10.1016\/j.clinthera.2021.05.015_bib0035","doi-asserted-by":"crossref","first-page":"213","DOI":"10.2217\/pgs-2017-0140","article-title":"Potential therapeutic and economic value of risk-stratified treatment as initial treatment of multiple myeloma in Europe","volume":"19","author":"Gaultney","year":"2018","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.clinthera.2021.05.015_bib0036","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1007\/s00259-018-3941-3","article-title":"ImmunoPET imaging of CD38 in murine lymphoma models using (89)Zr-labeled daratumumab","volume":"45","author":"Kang","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.clinthera.2021.05.015_bib0037","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1093\/annonc\/mdx201","article-title":"Cost-effectiveness of palbociclib in hormone receptor-positive advanced breast cancer","volume":"28","author":"Mamiya","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clinthera.2021.05.015_bib0038","doi-asserted-by":"crossref","first-page":"E68","DOI":"10.1002\/ajh.25372","article-title":"Daratumumab vs pomalidomide for the treatment of relapsed\/refractory multiple myeloma: a cost-effectiveness analysis","volume":"94","author":"Gong","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clinthera.2021.05.015_bib0039","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s40273-016-0458-0","article-title":"A review of US drug costs relevant to Medicare, Medicaid, and commercial insurers post-Affordable Care Act Enactment, 2010-2016","volume":"35","author":"McRae","year":"2017","journal-title":"Pharmacoeconomics"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291821002307?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291821002307?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:54:41Z","timestamp":1758963281000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291821002307"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":39,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["S0149291821002307"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2021.05.015","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"First-line Daratumumab in Addition to Chemotherapy for Newly Diagnosed Multiple Myeloma Patients Who are Transplant Ineligible: A Cost-Effectiveness Analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2021.05.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}